Seroatlas · Human Serome Atlas

BUD31

Protein BUD31 homolog

Also known as: BUD31_HUMAN, Cwc14, EDG-2, EDG2, fSAP17, G10, YCR063W

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P41223
Gene: BUD31
Ensembl: ENSG00000106245
Chromosome: 7
Canonical length: 144 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Microtubules,Centrosome

OverviewNCBI Gene

Enables nuclear receptor binding activity and transcription coactivator activity. Involved in mRNA splicing, via spliceosome. Located in centrosome; chromatin; and nucleoplasm. Part of U2-type catalytic step 2 spliceosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

144 residues, UniProt reviewed canonical sequence.

>P41223|BUD31
     1  MPKVKRSRKA PPDGWELIEP TLDELDQKMR EAETEPHEGK RKVESLWPIF RIHHQKTRYI
    61  FDLFYKRKAI SRELYEYCIK EGYADKNLIA KWKKQGYENL CCLRCIQTRD TNFGTNCICR
   121  VPKSKLEVGR IIECTHCGCR GCSG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BUD31 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 87 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 87 nTPM
choroid plexus: 74 nTPM
amygdala: 66 nTPM
basal ganglia: 65 nTPM
testis: 64 nTPM
midbrain: 64 nTPM

Single-cell type

esophageal apical cells: 512 nCPM
late primary spermatocytes: 485 nCPM
esophageal suprabasal cells: 281 nCPM
gastric progenitor cells: 273 nCPM
epididymal principal cells: 245 nCPM
esophageal basal cells: 228 nCPM

Immune cell

eosinophil: 519 nTPM
neutrophil: 454 nTPM
basophil: 393 nTPM
total PBMC: 361 nTPM
non-classical monocyte: 254 nTPM
intermediate monocyte: 233 nTPM

Brain region

thalamus: 32 nTPM
cerebellum: 31 nTPM
white matter: 27 nTPM
choroid plexus: 25 nTPM
hippocampal formation: 25 nTPM
hypothalamus: 25 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.87
gnomAD pLI: 0.23
gnomAD missense Z: 1.34
DepMap mean gene effect: -2.21
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

via spliceosome
mRNA splicing

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

Pre-mRNA-splicing factor BUD31
BUD31/G10-related, conserved site
Pre-mRNA-splicing factor BUD31

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BUD31 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BUD31 as an antibody target. Whether an autoantibody or antibody against BUD31 could matter depends on whether native BUD31 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BUD31 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BUD31 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...